Biosimilar Comparison Data
Buy and sell biosimilar comparison data data. Biosimilar vs originator efficacy, pricing, and market share — the follow-on biologic data.
No listings currently in the marketplace for Biosimilar Comparison Data.
Find Me This Data →Overview
What Is Biosimilar Comparison Data?
Biosimilar comparison data encompasses efficacy metrics, pricing analysis, and market share information comparing follow-on biologic products to their originator counterparts. This data is critical for pharmaceutical manufacturers, payers, and healthcare systems evaluating treatment alternatives. Biosimilars are regulatory-approved products that demonstrate sufficient similarity to reference biologics in quality, biological activity, safety, and efficacy. The market for biosimilars has grown substantially, with biosimilar products increasing their market share from just 1% in 2013 to 22% by 2023 across key therapy areas, driven by patent expiries of blockbuster biologics and the need for more affordable treatment options. Comparison data helps stakeholders understand competitive positioning, cost-effectiveness, and clinical outcomes across oncology, autoimmune, diabetes, and obesity indications.
Market Data
USD 72.29 billion
Global Biosimilars Market Size (2035)
Source: MarketsandMarkets
7.5%
Projected CAGR (2025–2035)
Source: MarketsandMarkets
22% of accessible market
Biosimilar Market Share by Volume (2023)
Source: OECD Health at a Glance 2025
USD 16.64 billion
Europe Biosimilars Market Size (2025)
Source: Fortune Business Insights
Who Uses This Data
What AI models do with it.do with it.
Pharmaceutical Manufacturers
Biosimilar manufacturers and originator biologic companies use comparison data to assess competitive positioning, pricing strategies, and market share dynamics across therapeutic areas.
Healthcare Payers & Systems
Third-party payers and healthcare systems leverage efficacy and pricing comparisons to inform formulary decisions, cost containment strategies, and reimbursement policies for both biosimilars and originator products.
Regulatory & Market Analysts
Regulatory bodies and market research firms use biosimilar comparison data to monitor patent expiries, track new approvals, and evaluate market entry patterns across regions and therapeutic classes.
Clinical Decision-Making
Healthcare providers and clinicians reference efficacy and safety comparisons to guide treatment selection and patient counseling for conditions in oncology, autoimmune disease, and endocrinology.
What Can You Earn?
What it's worth.worth.
Market Research Reports
Pricing varies based on volume, exclusivity, and licensing terms
Note: Market research reports about this category are sold by firms like Future Market Insights and Research Nester, but actual data licensing prices are negotiated case-by-case based on volume and scope.
Comparative Efficacy Data
Varies
Customized datasets comparing efficacy, safety, and outcomes command premium pricing based on therapeutic area, patient population size, and data granularity.
Pricing & Market Share Analytics
Varies
Regional and longitudinal pricing comparisons, particularly for oncology and autoimmune indications, are valued by payers and manufacturers at rates reflecting data exclusivity and update frequency.
What Buyers Expect
What makes it valuable.valuable.
Regulatory Accuracy
Data must reflect actual FDA, EMA, and international regulatory approvals; comparison metrics must be grounded in regulatory submissions and approved labeling.
Clinical Evidence Documentation
Efficacy and safety comparisons should be supported by published clinical trials, real-world evidence, and pharmacovigilance data demonstrating biosimilar similarity to originator products.
Transparent Pricing & Market Data
Pricing comparisons must document list prices, net prices, and regional reimbursement variations; market share data should clarify methodologies and patient volume calculations.
Longitudinal & Accessible Market Coverage
Data should track market dynamics over time, distinguish between patent-protected and accessible markets, and segment by therapeutic indication and drug class (mAbs, GCSF, insulin, GLP-1, etc.).
Continuous Monitoring & Updates
Buyers expect regular evaluation and monitoring systems tracking cost impact, treatment effectiveness, and new approvals to support real-time policy and procurement decisions.
Companies Active Here
Who's buying.buying.
Develop competitive pricing strategies, monitor market share erosion from biosimilar entry, and assess R&D ROI for patent-expiring biologics across oncology and autoimmune indications.
Evaluate cost-effectiveness of biosimilar adoption, negotiate reimbursement rates, and design formulary strategies to maximize cost containment while maintaining access.
Monitor biosimilar approvals, patent expiries, and competitive dynamics; inform pricing policies and accessibility improvements in key therapy areas.
Assess manufacturing complexity, economies of scale, and production cost benchmarks to optimize biosimilar production efficiency and competitive pricing.
FAQ
Common questions.questions.
How is market share calculated for biosimilar comparison data?
Market share is calculated based on the accessible market, defined as consumption volume (in treatment days) of originator biologics that have lost market exclusivity plus corresponding biosimilars. This includes three categories: reference medicines (originator biologics with approved biosimilars), non-referenced market (biologics without approved biosimilars), and biosimilars themselves, excluding originator products still under patent protection.
What therapeutic areas are most covered in biosimilar comparison datasets?
Primary therapeutic areas include oncology, autoimmune diseases (arthritis, psoriasis), diabetes, obesity, and specialty indications. Drug classes commonly compared include monoclonal antibodies (adalimumab, infliximab, rituximab, trastuzumab), filgrastim/pegfilgrastim (GCSF), insulin, anticoagulants, recombinant human growth hormone (rhGH), teriparatide, and GLP-1 products.
What factors drive demand for biosimilar comparison data?
Key drivers include rising incidence of chronic diseases, increasing patent expiries of blockbuster biologics, regulatory approval pathways creating new market entrants, and healthcare systems seeking affordable alternatives to expensive biologic therapies. Emerging manufacturers with cost-efficient capabilities and GLP-1 biosimilar launches are reshaping competitive dynamics.
How has biosimilar market penetration evolved?
Biosimilars have grown from 1% of accessible market volume in 2013 to 22% by 2023 across 25 countries and ten key therapy areas. In 2023, biosimilars accounted for more than one-quarter of the accessible market in selected therapy areas in countries including Italy, Spain, Sweden, Austria, and Portugal, reflecting steady acceptance and healthcare system integration.
Sell yourbiosimilar comparisondata.
If your company generates biosimilar comparison data, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.
Request Valuation